BEGIN:VCALENDAR PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN VERSION:2.0 BEGIN:VEVENT DESCRIPTION:15th Biosimilars Congregation 2021\n\n23rd - 24th June 2021\, Virtual Conference (Time Zone - BST)\n\nOur 15thBiosimilars Congregation 2021 will provide insight into the current state of play in the EU and st imulate debate\, in a multi-stakeholder setting\, on the vital role of bi osimilar medicines in the sustainability of healthcare systems. Beyond a comprehensive outlook of key European market access policies\, our speake rs will outline the key recent developments in regulatory science and reg ulatory policy in the EU and other international jurisdictions. This Bios imilars conference will focus on multiple aspects of Biosimilar product d evelopment to successfully deliver safe\, Biosimilar products to the mark et place. By attending this conference\, you will gain a comprehensive ou tlook on the key issues surrounding Biosimilars. This event will provide an important platform for Biosimilars stakeholders to discuss and share b est practices in furthering Biosimilars development.\n\nDELEGATE REGISTRA TION:\n\nEmail: kavitha@virtueinsight.co.in  \;or Call: +44-20 3509 3 779\n\nPlease note that this is a PAID event and NOT A FREE event (no com plimentary passes available). Any invite\, email or tickets issued mentio ning it as a free pass or free ticket to this event through any third par ty site will strictly not be accepted by the organizer. \n\nEARLY BIRD PR ICE\n\n1 Delegate @ £300 +VAT (Valid Till 17th May 2021)\n\n3 Delegates @ £700 +VAT (Valid Till 17th May 2021)\n\nSTANDARD PRICE\n\n1 Delegate @ £ 500 +VAT (Valid From 18th May 2021)\n\n3 Delegates @ £1200 +VAT (Valid Fr om 18th May 2021)\n\nConference Sponsor\, Exhibition Stall &\; Paid Sp eaker Slot - Please email your interest and queries to kavitha@virtueinsi ght.co.in\n\nKEY SPEAKERS:\n\n\nFREDRIK SUNDBERG\, Global Director\, Stra tegic Technology Partnership\, Cytiva (Formerly GE Life Sciences)\nRAJESH DESIKAN\, Vice President &\; Head\, US Marketing\, Oncology &\; Im munology Biosimilars\, Fresenius-Kabi\nJULIE MARECHAL JAMIL\, Director Bi osimilar Policy &\; Science\, Medicines for Europe\nMATTHEW TURNER\, S enior Director Government Affairs and Policy Biosimilars Europe\, Asia\, Latam &\; Canada\, Fresenius Kabi\nCECIL NICK\, Vice President\, Parex el\nANNA AILLERIE\, Brand Management Lead\, Europe\, Dr Reddy’s Laborator ies SA\nMIGUEL NAVARRETE OLMEDO\, Hospital &\; Biosimilars Commercial Director\, STADA Arzneimittel\nLOUIS BOON\, CSO\, Polpharma Biologics\nHA NMANT BARKATE\, Vice President &\; Head Medical Services (India\, MEA) \, Glenmark\nSWEETY MATHEW\, Regulatory Affairs\, Biocon\nMARTA BALDRIGHI \, Policy &\; Science Officer\, Medicines for Europe\nNIKLAS EKMAN\, H ead of the Biological Section\, Finnish Medicines Agency\nOMAR ALI\, Phar macist Consultant\, QIPP Adviser Payer Network\nRENE ANOUR\, Senior Clini cal Expert/Head of National Scientific Advice\, Austrian Medicines &\; Medical Devices Agency (AGES)\nBER OOMEN\, Executive Director\, ESNO (Eu ropean Specialist Nurses Organisations)\nMICHEL MIKHAIL\, International E xpert in Biosimilars\, Global Expert in Regulatory Affairs\, Michel Mikha il\nLENNEKE DE WINTER\, Senior Scientist USP\, Polpharma Biologics\nJAAP WIELING\, CSO\, BiosanaPharma\nJAKOB LANGE\, Senior Director Delivery Sys tems\, Ypsomed\nANDREAU SOLDEVILA\, Founder and CEO\, Syna Therapeutics\n INGRID SCHWARZENBERGER\, Senior Regulatory Consultant\, Independent Consu ltant\nBERT THOMAS\, Senior Vice President\, Business Development\, Bio-T hera Solutions\nSANDY EISEN\, Chief Medical Officer\, Frontline Pharma Co nsulting Ltd\nZIQUN HAN\, Director\, Zen Medical Science\nMARIE MANLEY\, Partner\, Head of the UK Life Sciences\, Sidley Austin\nALEXANDER ROUSSAN OV\, Life Sciences Regulatory and Privacy Lawyer\, Arnold &\; Porter\n ROBERT A. JOHNSTONE\, Board Member\, International Alliance of Patients O rganisations\nJOHAN DE MUNTER\, Assistant Nurse Manager Cancer Center\, P resident\, University Hospital Ghent\, European Oncology Nursing Society\ nMARC MARTENS\, Partner\, Bird &\; Bird\n\nKEY THEMES:\n\n\nStrategies for market access and expansion by identifying key changes and future pr ojections\nUnderstanding the biosimilars opportunity for pharma companies \nConsequences of Brexit &\; this pandemic situation on Biosimilars\nC urrent Challenges and Opportunities for future- Strategies in developing Biosimilars\nA Clinician ?s Guide to Biosimilars in Oncology: understandi ng the Science of Extrapolation and Interchangeability\nBiosimilars – Pri cing &\; Market access - Bringing it faster into market\nGMP\, GCP\, Q C &\; R&\;D\nCurrent challenges and opportunities - strategies to d evelop Biosimilars\nPayer perspective on biologics and Biosimilars\nBiosi milar Interchangeability: The newest regulation\nBiosimilar - Physicians and Patients perspective\nCMC\, Preclinical and clinical considerations f or Biosimilars and Follow-on Biologics\nImpact of Technology\nCommercial landscape &\; market access for Biosimilars: Predicts to prepare for a successful tomorrow\nHear case studies on biosimilars drug development f rom pre-clinical to clinical and the various testing required such as imm unogenicity and bio-similarity tests\nResearch-based industry Biosimilar strategies\nConsiderations for the analytical similarity assessments when designing a Biosimilar development program\nDetermining the right invest ments &\; potential returns from Biosimilars\nLatest developments in r egulation to increase speed of entry and compliance\nFuture of next gener ation biosimilars\nBe part of a major networking opportunity\n\nGet more from the event\, enjoy and make the best out of our dedicated networking drinks time\, meet the leading international vendors showcasing the produ cts of tomorrow in the co-located exhibition. Expand your knowledge of th e latest business models and strategies in the high-level conference. Whe ther you are on the branded or generic side\, you cannot afford to miss t his opportunity to benchmark your tactics and strategies against the indu stry leaders who will be the first to traverse the pathway.\n DTEND:20210624T170000 DTSTAMP:20260512T225908Z DTSTART:20210623T090000 LOCATION:\, SEQUENCE:0 SUMMARY:15th Biosimilars Congregation 2021\n23rd - 24th June 2021\, Virtua l Conference (Time Zone - BST)\nOur 15thBiosimilars Congregation 2021 wil l provide... UID:327a9d1e-f5c7-48a4-90aa-5f3eeb3ae112 END:VEVENT END:VCALENDAR